AU2023205787A1 - Methods of treating idiopathic pulmonary fibrosis with deupirfenidone - Google Patents

Methods of treating idiopathic pulmonary fibrosis with deupirfenidone Download PDF

Info

Publication number
AU2023205787A1
AU2023205787A1 AU2023205787A AU2023205787A AU2023205787A1 AU 2023205787 A1 AU2023205787 A1 AU 2023205787A1 AU 2023205787 A AU2023205787 A AU 2023205787A AU 2023205787 A AU2023205787 A AU 2023205787A AU 2023205787 A1 AU2023205787 A1 AU 2023205787A1
Authority
AU
Australia
Prior art keywords
subject
treatment
lyt
pirfenidone
tid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023205787A
Other languages
English (en)
Inventor
Michael C. Chen
Eric Elenko
Paul Andrew FORD
Varun Garg
Camilla S. GRAHAM
Simon John HATCH
Christopher C. KORTH
Julie S. KROP
Liza C. MICIONI
Heather A. PADEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Puretech LYT 100 Inc
Original Assignee
Puretech LYT 100 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Puretech LYT 100 Inc filed Critical Puretech LYT 100 Inc
Publication of AU2023205787A1 publication Critical patent/AU2023205787A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2023205787A 2022-01-05 2023-01-05 Methods of treating idiopathic pulmonary fibrosis with deupirfenidone Pending AU2023205787A1 (en)

Applications Claiming Priority (31)

Application Number Priority Date Filing Date Title
US202263296826P 2022-01-05 2022-01-05
US202263296818P 2022-01-05 2022-01-05
US202263296843P 2022-01-05 2022-01-05
US63/296,843 2022-01-05
US63/296,826 2022-01-05
US63/296,818 2022-01-05
US202263326132P 2022-03-31 2022-03-31
US202263326129P 2022-03-31 2022-03-31
US63/326,132 2022-03-31
US63/326,129 2022-03-31
US202263341269P 2022-05-12 2022-05-12
US202263341279P 2022-05-12 2022-05-12
US202263341281P 2022-05-12 2022-05-12
US63/341,281 2022-05-12
US63/341,269 2022-05-12
US63/341,279 2022-05-12
US202263341828P 2022-05-13 2022-05-13
US63/341,828 2022-05-13
US202263352107P 2022-06-14 2022-06-14
US63/352,107 2022-06-14
US202263356653P 2022-06-29 2022-06-29
US63/356,653 2022-06-29
US202263374362P 2022-09-01 2022-09-01
US63/374,362 2022-09-01
US202263403481P 2022-09-02 2022-09-02
US63/403,481 2022-09-02
US202263431530P 2022-12-09 2022-12-09
US63/431,530 2022-12-09
US202263432208P 2022-12-13 2022-12-13
US63/432,208 2022-12-13
PCT/US2023/060185 WO2023133476A1 (en) 2022-01-05 2023-01-05 Methods of treating idiopathic pulmonary fibrosis with deupirfenidone

Publications (1)

Publication Number Publication Date
AU2023205787A1 true AU2023205787A1 (en) 2024-06-13

Family

ID=87074293

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023205787A Pending AU2023205787A1 (en) 2022-01-05 2023-01-05 Methods of treating idiopathic pulmonary fibrosis with deupirfenidone

Country Status (9)

Country Link
US (1) US20240358690A1 (https=)
EP (1) EP4460305A4 (https=)
JP (1) JP2025502023A (https=)
KR (1) KR20240131352A (https=)
AU (1) AU2023205787A1 (https=)
CA (1) CA3239301A1 (https=)
IL (1) IL314022A (https=)
MX (1) MX2024008476A (https=)
WO (1) WO2023133476A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025511066A (ja) * 2022-03-31 2025-04-15 ピュアテック・エル・ワイ・ティ・１００・インコーポレイテッド デューピルフェニドンにより間質性肺疾患ならびに他の線維化介在性肺疾患及び障害を治療する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
WO2009035598A1 (en) * 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
EP4603148A3 (en) * 2018-09-14 2025-10-29 Puretech Lyt 100, Inc. Deuterium-enriched pirfenidone and methods of use thereof
CA3171622A1 (en) * 2020-03-13 2021-09-16 Puretech Lyt 100, Inc. Methods of treating respiratory disease with deupirfenidone

Also Published As

Publication number Publication date
JP2025502023A (ja) 2025-01-24
WO2023133476A1 (en) 2023-07-13
US20240358690A1 (en) 2024-10-31
EP4460305A1 (en) 2024-11-13
MX2024008476A (es) 2024-07-12
EP4460305A4 (en) 2025-12-31
IL314022A (en) 2024-08-01
CA3239301A1 (en) 2023-07-13
KR20240131352A (ko) 2024-08-30

Similar Documents

Publication Publication Date Title
Kopp European S3-guidelines on the systemic treatment of psoriasis vulgaris
EP3972603B1 (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
AU2025203171A1 (en) A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis
Boettcher et al. Vericiguat in combination with short‐acting nitroglycerin in patients with chronic coronary syndromes: the randomized, phase Ib, VENICE study
US20240358690A1 (en) Methods of treating idiopathic pulmonary fibrosis with deupirfenidone
US20250249001A1 (en) Methods of treating substance use disorder with 4-(3-cyanophenyl)-6-pyridinylpyrimidine mglu5 negative allosteric modulators
US20250114341A1 (en) Methods of treating idiopathic pulmonary fibrosis with deupirfenidone
HK40114519A (zh) 用氘吡非尼酮治疗特发性肺纤维化的方法
US20250114340A1 (en) Methods of treating interstitial lung diseases and other fibrotic-mediated pulmonary diseases and disorders with deupirfenidone
CN118510510A (zh) 用氘吡非尼酮治疗特发性肺纤维化的方法
US20210137903A1 (en) Anti-androgens for the treatment of prostrate cancer
TW202237078A (zh) 使用德弗米司特(devimistat)治療肉瘤之治療方法及組合物
Groseanu et al. FRI0256 Significance of cognitive impairment in systemic sclerosis
US20240122928A1 (en) Methods For Treating Agitation In Subjects With Mild Cognitive Impairment Or Major Neurocognition Disorder
RU2824354C2 (ru) Способы лечения синдрома шегрена с применением ингибитора тирозинкиназы брутона
DEVELOPM Drug DeveloPment
Antoniu Pirfenidone for the treatment of idiopathic pulmonary fibrosis: therapeutic potential prompts further investigation: AZUMA A, NUKIWA T, TSUBOI E et al.: Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.(2005) 171 (9): 1040-1047.
US20120052122A1 (en) Treatment Of Chronic Obstructive Pulmonary Disease With Phosphodiesterase-4 Inhibitor
TW202535397A (zh) 給藥方案
US20230381190A1 (en) Methods and Treatment for Complex Lymphatic Malformations
WO2020144646A1 (en) Apalutamide dispersed in applesauce for treating prostate cancer
WO2024173873A2 (en) Compounds, compositions, and methods for treating, ameliorating, and/or preventing pain
EA051453B1 (ru) Способы лечения и профилактики рассеянного склероза с применением соединений замещенного аминопиримидина
Bruck et al. CLINICAL PHARMACOLOGY SECTION 19–22 DECEMBER 2005 Institute of Education,(hosted by University College London)
John The extra-pulmonary effects of chronic obstructive pulmonary disease (COPD)